	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Sep 30
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Sep 30
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	28.60	48.84	73.15	57.98	103.83	96.99	101.24	104.78
Cost of Operating Revenue	22.83	41.99	57.10	41.69	82.71	72.15	69.91	85.51
Gross Profit	5.78	6.86	16.05	16.29	21.12	24.84	31.32	19.27
Gross Margin	20.2	14.0	21.9	28.1	20.3	25.6	30.9	18.4
Total Operating Expenses	28.14	49.98	66.31	51.40	98.65	87.17	88.57	99.77
Operating Profit	0.46	-1.14	6.84	6.58	5.18	9.81	12.67	5.01
Operating Margin	1.6	-2.3	9.4	11.4	5.0	10.1	12.5	4.8
Financing Income/(Expense) - Net	-0.33	-1.02	-0.53	-0.86	-1.70	-2.01	-3.92	-1.81
Profit before Taxes	0.36	-2.06	4.69	5.96	3.96	11.12	8.70	4.29
Income Taxes	0.27	0.31	1.82	1.47	0.38	1.84	2.40	0.14
Profit after Tax	0.09	-2.37	2.88	4.50	3.58	8.03	5.77	4.15
PAT Margin	0.3	-4.8	3.9	7.8	3.4	8.3	5.7	4.0
EPS - Basic - ex Extraordinary Items	0.08	-2.14	2.61	4.07	3.24	7.26	5.22	3.76
EPS - Diluted - ex Extraordinary Items	0.08	-2.14	2.61	4.07	3.24	7.26	5.22	3.76
EBIT	0.46	-1.14	6.84	6.58	5.18	9.81	12.67	5.01
EBITDA	1.86	1.45	7.97	8.21	8.28	13.65	18.07	8.21
EBITDA Margin	6.5	3.0	10.9	14.2	8.0	14.1	17.9	7.8

Balance Sheet

Abridged

Understanding Balance Sheet

Sotac Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	AR	AR	AR	AR
Total Current Assets	13.75	17.35	25.88	36.61	60.65	69.83	77.68
Long-Term Investments	-	0.13	0.39	4.00	2.10	3.78	2.92
Property Plant & Equipment - Net	15.99	16.56	8.79	14.09	33.59	46.77	45.77
Total Non-Current Assets	16.63	17.35	9.38	18.18	44.68	54.50	55.79
Total Assets	30.38	34.70	35.25	54.78	105.33	124.33	133.47
Total Current Liabilities	19.34	22.76	27.61	27.11	43.73	51.55	58.36
Long Term Debt	6.15	9.28	0.97	6.59	12.13	14.19	10.39
Total Non-Current Liabilities	7.98	9.44	1.03	16.15	12.27	14.36	10.54
Total Liabilities	27.32	32.20	28.63	43.26	56.00	65.91	68.90
Total Shareholders' Equity	3.06	2.49	6.62	11.52	45.26	53.25	58.87
Minority Interest	-	-	-	-	4.07	5.17	5.70
Total Equity	3.06	2.49	6.62	11.52	49.33	58.42	64.57
Total Liabilities & Equity	30.38	34.70	35.25	54.78	105.33	124.33	133.47

Cash Flow

Abridged

Understanding Cash Flow Statement

Sotac Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	1.80	0.34	5.78	5.83	2.54	14.16	11.92
Working Capital - Increase/(Decrease)	-2.03	-1.61	0.08	1.87	-20.31	-20.91	0.86
Net CF from Operating Activities	-0.23	-1.27	5.87	7.70	-17.77	-6.75	12.78
Capital Expenditures - Net	9.80	3.16	3.50	6.96	17.78	12.09	7.81
Net CF from Investing Activities	-11.79	-3.29	-3.56	-10.96	-19.73	-13.78	-6.95
Dividends Paid - Cash - Total	-	-	-	-	-	-	0.11
Stock - Issuance/(Retirement) - Net	5.25	-	-	9.47	33.30	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	5.75	4.19	0.71	-2.27	4.40	2.06	-6.10
Net Cash Flow from Financing Activities	11.73	4.40	-2.30	12.83	31.24	18.67	-6.21
Free Cash Flow to Equity	-4.28	-0.24	3.07	-1.52	-31.15	-16.78	-1.14
Free Operating CF net dividend	-10.03	-4.43	2.36	0.66	-35.56	-23.76	4.77
Free Operating CF	-10.03	-4.43	2.36	0.66	-35.56	-23.76	4.88

Business Segment Analysis

Sotac Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Sotac Pharmaceuticals Ltd.

Regional Segment Analysis

Sotac Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Sotac Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Sotac Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Sotac Pharmaceuticals Ltd.

Frequently Asked Questions

What is the revenue of Sotac Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Sotac Pharmaceuticals Ltd. is ₹ 101.24 Cr, reflecting a 1-year growth of 4.38% and a 3-year CAGR of 20.42%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sotac Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Sotac Pharmaceuticals Ltd. is ₹ 5.77 Cr, with a 3-year earnings CAGR of 8.66%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sotac Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Sotac Pharmaceuticals Ltd. is approximately ₹ 12.48 Cr (based on an operating margin of 12.32%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sotac Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sotac Pharmaceuticals Ltd. is 5.22. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sotac Pharmaceuticals Ltd.?

The debt-to-equity ratio of Sotac Pharmaceuticals Ltd. stands at 0.64. The interest coverage ratio is 3.02x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sotac Pharmaceuticals Ltd.?

The estimated book value per share of Sotac Pharmaceuticals Ltd. is 53.28 (derived from a P/B ratio of 1.73 and market price of ₹ 92.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sotac Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Sotac Pharmaceuticals Ltd. is ₹ 12.79 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sotac Pharmaceuticals Ltd. report consolidated or standalone financials?

Sotac Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.